Immutep Ltd Stock News

SYDNEY, Australia, June 22, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate.

Shares in Immutep (IMMP) are surging 10% in Monday’s pre-market trading after the company announced first interim data from its ongoing INSIGHT-004 Phase I clinical trial at the 2020 American Societ

Presented at ASCO 2020 Annual Meeting First complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC)Improving Overall Response Rate (iORR) in HNSCC,.

First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCOEncouraging early activity signals in a variety.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A

SYDNEY, Australia, May 29, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for.

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma

SYDNEY, Australia, May 27, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST).

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Immutep (IMMP), with a price target of $2.00. The company's shares

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Immutep (IMMP – Research Report),

SYDNEY, Australia, April 30, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two.

Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC):    º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%)    º.

The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s

Immutep reports enrollment completed for INSIGHT-004 study IMMP MKGAY PFE

Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and...